← Home
Sleep Unplugged · October 12, 2026 · 46m

#225 - Orexin Agonist Update: The Big Reward is Here (Lifting Humanity Higher)

This episode revisits the orexin agonist landscape less than a year after first introducing the three companies racing to market. It breaks down the latest data from the SLEEP 2026 meeting in Baltimore, the FDA approval of Orzeyful (oveporexton), and the $6.3 billion acquisition of Centessa by Eli Lilly for cleminorexton. Dr. Chris Winter also addresses practical questions from patients about controlled substance scheduling, insurance coverage, and cost.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Preview

•
SLEEP 2026 data shows rapid orexin agonist progress
The SLEEP 2026 meeting in Baltimore presented the latest data on orexin agonists, showing rapid progress from three competitors to an approved drug and a multi-billion-dollar acquisition within a year.
ClaudeChatGPTGemini
•
FDA approval of Orzeyful (oveporexton)
Orzeyful (oveporexton) became the first orexin agonist to receive FDA approval for narcolepsy.
ClaudeChatGPTGemini

1 more ideas & all timestamps

This episode is in its early-access window. The full breakdown unlocks free in about 69 hours — Pro members read everything the moment it lands.

Read it now with Pro$10/mo · founding $96/yr
Was this useful?